Market Overview:
The global metastatic bones cancer market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of bone cancer, rising awareness about metastatic bone cancer, and technological advancements in the field of oncology. Based on type, the global metastatic bones cancer market can be segmented into medication, radiation therapy, surgical intervention, and tumor ablation therapy. The medication segment is expected to account for the largest share of the global metastatic bones cancer market in 2018. This segment is projected to grow at a CAGR of 7.8% during the forecast period from 2018 to 2030 due to increasing use of targeted therapies and immunotherapies for treatment of bone cancers. Based on application, hospitals are expected to account for the largest share of the global metastatic bones cancer market in 2018 followed by clinics.
Product Definition:
Metastatic cancer is a type of cancer that has spread from the original tumor site to other parts of the body. Metastatic bones cancer is a specific type of metastatic cancer that has spread to the bones. This type of cancer can cause severe pain and bone damage. Treatment options include chemotherapy, radiation therapy, and surgery.
Medication:
Medication is any substance or device that is given to a patient by a doctor, usually to treat an illness or disease. Medications are used for the treatment of cancer in several different ways. One of the most common uses for medication in oncology is as an anti-cancer drug, which helps slow down or stop cancer from growing and spreading.
The global medication market size was valued at USD 459 billion in 2016.
Radiation Therapy:
Radiation therapy is a form of cancer treatment that uses high energy waves to cure the cancer. The radiation oncologists or radiotherapists direct the beam at specific body parts using X-rays, gamma rays, or ionizing radiation. Radiation therapy can be used for various types of cancers such as brain, lung, breast and bone metastatic tumors.
Application Insights:
Based on application, the market is segmented into hospitals, clinics and other medical centers, and others. Hospitals held the largest share in 2017 owing to availability of advanced treatment facilities for metastatic bones cancer patients. Moreover, hospitals provide better care due to highly skilled staff with experience in handling complex cases related to bone metastasis.
Clinics and other medical centers are projected to witness lucrative growth over the forecast period due largely to increasing awareness about early diagnosis coupled with rising disposable income levels among people across various regions of the world. As per a study published by NCBI in 2018 regarding economic burden of cancer worldwide, it was estimated that around 1 in 6 women as well as 1 in 5 men will develop some form of cancer during their lifetime globally which amounted up an overall cost of USD 8 trilobytes for females & males combined globally every year since 2012 till 2060 CE (Cumulative Exponential Growth).
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing R&D activities and high healthcare expenditure. In addition, favorable reimbursement policies are also aiding in growth of the regional market. For instance, under Medicare Part B coverage, patients with metastatic bone cancer may be reimbursed for some of their out-of-pocket expenses related to medically necessary services and supplies provided by physicians at outpatient facilities such as hospitals or clinics that are participating in Medicare/ Medicaid programs.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising geriatric population base.
Growth Factors:
- Increasing incidence of metastatic bones cancer
- Growing awareness about metastatic bones cancer and its symptoms
- Rising number of research and development activities for the treatment of metastatic bones cancer
- Technological advancements in the diagnosis and treatment of metastatic bones cancer
- increasing healthcare expenditure
Scope Of The Report
Report Attributes
Report Details
Report Title
Metastatic Bones Cancer Market Research Report
By Type
Medication, Radiation Therapy, Surgical Intervention, Tumor Ablation Therapy
By Application
Hospitals, Clinics, Others
By Companies
Amgen, Merck & Co, Roche, Novartis, Eli Lilly and Company, Bayer, Fresenius Kabi, BTG plc, Boston Scientific, Medtronic
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
172
Number of Tables & Figures
121
Customization Available
Yes, the report can be customized as per your need.
Global Metastatic Bones Cancer Market Report Segments:
The global Metastatic Bones Cancer market is segmented on the basis of:
Types
Medication, Radiation Therapy, Surgical Intervention, Tumor Ablation Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen
- Merck & Co
- Roche
- Novartis
- Eli Lilly and Company
- Bayer
- Fresenius Kabi
- BTG plc
- Boston Scientific
- Medtronic
Highlights of The Metastatic Bones Cancer Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Medication
- Radiation Therapy
- Surgical Intervention
- Tumor Ablation Therapy
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Metastatic Bones Cancer Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Metastatic bones cancer is a type of cancer that has spread from the original site to other parts of the body. This type of cancer is often found in the bones, but it can also occur in other tissues. Metastatic bones cancer is difficult to treat and may eventually lead to death.
Some of the key players operating in the metastatic bones cancer market are Amgen, Merck & Co, Roche, Novartis, Eli Lilly and Company, Bayer, Fresenius Kabi, BTG plc, Boston Scientific, Medtronic.
The metastatic bones cancer market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Metastatic Bones Cancer Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Metastatic Bones Cancer Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Metastatic Bones Cancer Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Metastatic Bones Cancer Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Metastatic Bones Cancer Market Size & Forecast, 2018-2028
4.5.1 Metastatic Bones Cancer Market Size and Y-o-Y Growth
4.5.2 Metastatic Bones Cancer Market Absolute $ Opportunity
Chapter 5 Global Metastatic Bones Cancer Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Metastatic Bones Cancer Market Size Forecast by Type
5.2.1 Medication
5.2.2 Radiation Therapy
5.2.3 Surgical Intervention
5.2.4 Tumor Ablation Therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Metastatic Bones Cancer Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Metastatic Bones Cancer Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Metastatic Bones Cancer Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Metastatic Bones Cancer Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Metastatic Bones Cancer Analysis and Forecast
9.1 Introduction
9.2 North America Metastatic Bones Cancer Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Metastatic Bones Cancer Market Size Forecast by Type
9.6.1 Medication
9.6.2 Radiation Therapy
9.6.3 Surgical Intervention
9.6.4 Tumor Ablation Therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Metastatic Bones Cancer Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Metastatic Bones Cancer Analysis and Forecast
10.1 Introduction
10.2 Europe Metastatic Bones Cancer Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Metastatic Bones Cancer Market Size Forecast by Type
10.6.1 Medication
10.6.2 Radiation Therapy
10.6.3 Surgical Intervention
10.6.4 Tumor Ablation Therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Metastatic Bones Cancer Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Metastatic Bones Cancer Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Metastatic Bones Cancer Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Metastatic Bones Cancer Market Size Forecast by Type
11.6.1 Medication
11.6.2 Radiation Therapy
11.6.3 Surgical Intervention
11.6.4 Tumor Ablation Therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Metastatic Bones Cancer Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Metastatic Bones Cancer Analysis and Forecast
12.1 Introduction
12.2 Latin America Metastatic Bones Cancer Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Metastatic Bones Cancer Market Size Forecast by Type
12.6.1 Medication
12.6.2 Radiation Therapy
12.6.3 Surgical Intervention
12.6.4 Tumor Ablation Therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Metastatic Bones Cancer Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Metastatic Bones Cancer Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Metastatic Bones Cancer Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Metastatic Bones Cancer Market Size Forecast by Type
13.6.1 Medication
13.6.2 Radiation Therapy
13.6.3 Surgical Intervention
13.6.4 Tumor Ablation Therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Metastatic Bones Cancer Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Metastatic Bones Cancer Market: Competitive Dashboard
14.2 Global Metastatic Bones Cancer Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen
14.3.2 Merck & Co
14.3.3 Roche
14.3.4 Novartis
14.3.5 Eli Lilly and Company
14.3.6 Bayer
14.3.7 Fresenius Kabi
14.3.8 BTG plc
14.3.9 Boston Scientific
14.3.10 Medtronic
